Phase 2 Trial With Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers: Big Ten Cancer Research Consortium BTCRC-BRE18-337

Status: Closed to Accrual

Learn more:

• https://clinicaltrials.gov/study/NCT03911973
• See Study Locations on Big Ten CRC Website

Study Contact: studies@hoosiercancer.org; (317) 921-2050.